DiagnosticsNews

Roche Diagnostics unveils point-of-care NT-proBNP test for screening diabetes patients

Roche Diagnostics India’s NT-proBNP test on the cobas h 232 system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions

Roche Diagnostics India has launched its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). The breakthrough innovation is designed to bring testing closer to clinics and revolutionise patient care. The claim extension of the NT-proBNP biomarker, available exclusively on the cobas h 232 system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D).  

Roche Diagnostics India’s NT-proBNP test on the cobas h 232 system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions. 

Dr Sanjay Kalra, Chief Endocrinologist, Bharti Hospital, Karnal, India, past president of the Endocrine Society of India (ESI), and Executive Committee member & Chair, Education Working Group at the International Society of Endocrinology (ISE), said the incorporation of NT-proBNP test extension onto convenient point-of-care platforms signifies a notable stride in diabetes care. This innovative biomarker, when integrated into primary care settings, enables us to proactively assess heart failure risks in patients with T2D, thereby fostering improved outcomes and bolstering patient well-being. 

Rishubh Gupta, MD, Roche Diagnostics India & Neighbouring markets emphasised the company’s commitment to driving patient-centric solutions. “At Roche, we are dedicated to advancing healthcare through innovation. The extended claim on our NT-proBNP test now available on our point-of-care system underscores our mission to empower clinicians with cutting-edge tools for early diagnosis and personalised patient care,” said Gupta.

 

 

 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
IndiaMedToday
Close
Close